loader2
Partner With Us NRI

Company details

49.15
50.30
38.70
77.70
6M Return 0.72%
1Y Return -28.71%
Mkt Cap.(Cr) 2,017.92
Volume 80,432
Div Yield 0.51%
OI
-
OI Chg %
-
Volume 80,432

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Rapid Results

Q1FY23 Quarterly Result Announced for Marksans Pharma Ltd.

Marksans Pharma announced Q1FY23 Result :

  • Operating revenue was Rs. 433.8 cr., growing by 24.3% driven by a strong volume growth in existing products and new launches in the US & UK.
    • US business grew by 25.7%. Pricing erosion in the US continued in the high single digit during the quarter impacting Generic Rx business.
    • UK and Europe grew by 13.7%
  • Gross profit was Rs 218.9 cr, growing by 17.3% YoY with Gross margin at 50.5%.
  • EBITDA was Rs 72.9 cr., declining by 5.8% with EBITDA margin at 16.8%, on account of increase in costs of material, freight costs, and pricing pressure in the US.
  • R&D spend was at 2% of sales
  • Healthy cash balance of Rs. 339 cr

Mark Saldanha, Managing Director of the Company said "We had a strong start to the year, achieving good growth across all our regions. Our existing business, new product approvals, and launches continue to drive the momentum. We have emerged as a prime manufacturer and marketer of private-label store brands of consumer healthcare products in the USA, UK and Australia. This is driven by our commitment to invest in product innovation, newer capacities, and increasing penetration. Looking ahead, we see growing demand in our OTC segment across the regions, and we are well-positioned to take advantage of these opportunities."

Result PDF

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 1,109.17 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 3,213.79 10,702.06
LAST 3M 4,765.78 66,293.35
LAST 6M 78,132.76 -40,125.32
LAST 12M 202,528.75 -192,001.24
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Aug 19, 2022 Dividend 25
Sep 15, 2021 Dividend 25
Sep 22, 2020 Dividend 10

Information

  • About Company
  • Company Info
  • Listing Info
10.93
48.25%
27.0983
22.83%
17.89%
Description
  • Marksans Pharma Limited is a pharmaceutical company and has a market capitalization of Rs. 2,916 crores as of 18th August 2021. The company started on 16th April 1992. The company has reported a total quarterly income of Rs.354.84 crores at the end of June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 524404 and scrip code MARKSANS. As of 18th August 2021, Marksans Pharma’s shares were trading at Rs. 71.25.

    The corporate is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company’s research and development centres are in Verna Goa and Navi Mumbai, respectively. With three manufacturing facilities in India, UK, and therefore the US, Marksans has established an authoritative position in regulated markets in India and abroad. The company currently has approximately 1200 employees globally with more than 500 registered products. It also has 50+ experienced scientists in the R& D facility. The promoter holding stood at 48.25% in June 2021 and has remained constant over the last 15 months. Promoters have zero pledged holdings.

    In June 2021, the company reported total revenue of Rs. 354.84 crores as compared to Rs. 336.21 crores during the quarter ended March 2021. It had posted net profit / (loss) of Rs. 62.60 crores for the period ended June 2021 as compared to net profit / (loss) of Rs.79.49 crores for the period ended 31st March 2021. The company’s EPS was at Rs.1.51 for the period ended 30th June '2021, as against Rs.1.93 for the period ended 31st March '2021. On a year-on-year basis, the total income of the company has increased 7.10% from Rs. 331.33 crores to Rs. 354.84 crores with the net profit increasing 26.82% from Rs. 49.36 crores to Rs. 62.60 crores and with EPS increasing 25.83% to Rs. 1.51 as against Rs. 1.2 in June 2020. Over the last 5 years, the company’s market share has increased from 0.49% to 0.54%. Marksans Pharma’s shares closed at Rs. 71.25 (NSE) as of 18th August 2021 and has given a return of 30.38% over the last 12 months.

     

Read More

Registered Address

11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Tel : 91-22-40012000
Email : companysecretary:marksanspharma.com
Website : http://www.marksanspharma.com

Registrar

Bigshare Services Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524404
NSE Code : MARKSANS
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE750C01026

ICICIdirect Marksans Pharma Ltd FAQ

You can buy Marksans Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Marksans Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 23, 2022 04:01 PM the closing price of Marksans Pharma Ltd was ₹ 49.30.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 23, 2022 04:01 PM, the market cap of Marksans Pharma Ltd stood at ₹ 2,017.92.
The latest PE ratio of Marksans Pharma Ltd as of Sep 23, 2022 04:01 PM is 10.93
The latest PB ratio of Marksans Pharma Ltd as of Sep 23, 2022 04:01 PM is 0.55
The 52-week high of Marksans Pharma Ltd is ₹ 77.70 while the 52-week low is ₹ 38.70 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE